(Q40845933)

24 September 2017

1 reference

title

Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis (English)

1 reference

24 September 2017

1 reference

Kavanaugh AF

1

1 reference

24 September 2017

1 August 1998

1 reference

Rheumatic Diseases Clinics of North America

24 September 2017

1 reference

24 September 2017

24

1 reference

24 September 2017

3

1 reference

24 September 2017

593-614

1 reference

Does tumor necrosis factor protect against lupus in west Africans?

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

The tumor necrosis factor ligand and receptor families.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Rheumatoid arthritis and the risk of malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Tumour necrosis factor in synovial exudates

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Critical protective role of mast cells in a model of acute septic peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Role of cytokines in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Anticytokine therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

How important are T cells in chronic rheumatoid synovitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Activation of transcription factor NF-kappa B in human synovial cells in response to tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Incidence of Cancer Among Patients With Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Association of tumor necrosis factor microsatellite polymorphisms with HLA-DRB1*04–bearing haplotypes in rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Rheumatoid arthritis. Pathophysiology and implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Tumor necrosis factor alpha in autoimmunity: pretty girl or old witch?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

1 reference

7 January 2021

Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor alpha receptor gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Balance of synovial fluid IL-1 beta and IL-1 receptor antagonist and recovery from Lyme arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Teetering on the brink of danger

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Pathogenesis of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

The mortality of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970028-4

7 January 2021

10.1016/S0889-857X(05)70028-4

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

9710889